Jeffrey J. Olson, MD

 Jeffrey J. Olson

Jeffrey J. Olson, MD
Professor, Department of Neurosurgery
Professor, Department of Hematology and Medical Oncology
Director, Clinically-related Neuro-oncology Laboratory
Co-director, Brain Tumor Program

The Emory Clinic, Building B, 2nd floor
1365-B Clifton Rd., NE, Ste. 2200
Atlanta, GA 30322

To make an appointment: 404-778-5770

Dr. Olson received his MD from the University of Minnesota and completed his neurosurgical residency training at the University of Iowa. He spent three years as a Senior Staff Fellow at the National Institutes of Health in Bethesda, Maryland. In 1990, Dr. Olson joined the faculty of Emory University's School of Medicine, where he continues to practice as a renowned neurosurgeon and professor of Neurosurgery, Hematology and Medical Oncology. He is also Principal Investigator for Emory for the National Cancer Institute Sponsored Adult Brain Tumor Consortium. In 2010, Dr. Olson was named President of the Georgia Neurosurgical Society.

Dr. Olson's primary interest is in neuro-oncology, also known as brain cancer. His neurosurgical practice and research involve the biology and therapy of brain tumors, and his primary area of research is clinical trials of new brain tumor therapies.

Clinical Trials

Dr. Olson's research is an important resource for patients who wish to participate in clinical trials for malignant brain tumors. Emory's multidisciplinary neuro-oncology team offers patients the option to participate in research studies that use a variety of innovative approaches for treating the molecular and anatomic characteristics of brain tumors. Professionals with basic science, medical oncology, neurology, radiology, radiation oncology and neurosurgical backgrounds collaborate to provide patients the best exposure to a range of treatment options. Learn more about clinical trials at Emory.


Areas of Clinical Interest:

  • acoustic neuroma
  • brain tumors (Emory PI for the NCI-sponsored New Approaches to Brain Tumor Therapies-CNS Consortium)
  • cerebrospinal fluid leakage
  • cranial nerve disorder
  • lesions of the anterior and posterior skullbase
  • stereotactic surgery

Return to top


Publications

Bingaman KD, Alleyene C, Olson JJ:  Intracranial extraskeletal mesenchymal chondrosarcoma.  Neurosurgery 46:  207-212, 2000. 

Schinazi RF, Hurwitz SJ, Liberman I, Juodawkis A, Shi J, Liotta DC, Coderre J, Olson J:  -5-o-Carboranyl-2'-deoxyuridine for the treatment of malignant brain tumors.  Clin Cancer Res 6:  725-730, 2000. 

Trounce I, Schmiedel J, Yen H-C, Hosseini S, Brown MD, Olson JJ, Wallace DC:  Cloning of neuronal mtDNA variants in cultured cells by synaptosome fusion with mtDNA-less cells.  Nucleic Acids Research 28:  2164-2170, 2000. 

Houston SC, Crocker IR, Brat DJ, Olson JJ:  Extraneural Metastatic Glioblastoma After Interstitial Brachytherapy.  Int J Radiat Oncol Biol Phys 48:  831-836, 2000.

Yung WKA, Albright RE, Olson J, Fredericks R, Fink K, Prados M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips R, Bruner J, Yue N, Osaba D, Zaknoen S, Levin VA:  A phase II study of temozolomide vs. procarbazine in patients with glioblastoma at first relapse.  Br J Cancer  83:  588-93, 2000. 

Sharara N, Muller S, Olson J, Grist WJ, Grossniklaus HE:  Sinonasal undifferentiated carcinoma with orbital invasion.  Ophthalmic Plastic and Recon Surg 4:  288-292, 2001

Stubbs J, Frankel R, Schultz K, Crocker I, Dillehay D, Olson JJ:  Pre-clinical evaluation of a novel device for delivering brachytherapy to resected brain tumor cavity margins. J Neurosurg 96:  335-343, 2002.  

Hunter S, Young A, Olson J, Brat DJ, Bowers G, Wilcox JN:  Differential expression between pilocytic and anaplastic astrocytoma:  identification of apoplipoprotein D as a marker for low-grade, non-infiltrating primary CNS neoplasms.  J Neuropathol Exp Neurol 61:  275-281, 2002. 

McConathy J, Martello L, Malveaux EJ, Camp VM, Simpson NE, Simpson, Bowers GD, Olson, JJ, Goodman MM:  Radiolabeled amino acids for tumor imaging with PET:  Radiosynthesis and biological evaluation of 2-amino-3-[18F]fluoro-2-methylpropanoic acid and 3-[18F]fluoro-2-methyl-2-(methylamino)propanoic acid.  J Med Chem 45:  2240-2249, 2002.

Selker RG, Shapiro W, Burger P, Blackwood, Deutsch M, Arena V, Van Gilder JC, Wu J, Malkin M, Mealey J, Jr, Neal J, Olson J, Robertson JT, Barnett G, Bloomfield S, Albright R, Hochberg FH, Heisigner E, Green S:  The Brain Tumor Cooperative Group NIH Trial 87-01:  A randomized comparison of surgery, external radiotherapy and BCNU v. surgery, interstitial radiotherapy boost, external radiation therapy and BCNU.  Neurosurgery 51:343-357, 2002.

Mayr MT, Crocker IR, Butker EK, Williams WH, Cotsonis GA, Olson JJ:  Results of interstitial brachytherapy for malignant brain tumors.  Int J Oncol.  21:817-823, 2002.

Martarello L, McConathy J, Camp VM, Malveaux EJ, Simpson NE, Simpson CP, Olson JJ, Gowers GD, Goodman MM:  Synthesis of syn- and anti-1-Amino-3-[18F]fluoromethyl-cyclobutane-1-carboxylic Acid (FMACBC), Potential PET Ligands for Tumor Detection.  J Med Chem 45: 2250-2259, 2002.

Gilbert MR, Friedman HS, Kuttesch JF, Prados MD, Olson JJ, Reaman GH, Zakonen SL:  A Phase II Study of Temozolomide in Patients With Newly Diagnosed, Supratentorial Malignant Glioma Prior to Radiation Therapy.  Neuro-Oncology:  261-267, October, 2002.

Lonser RR, Walbridge S, Vortmeyer AO, Pack SD, Nguyen TT, Gogate N, Olson JJ, Akbasak A, Bobo RH, Goffman T, Zhuang Z, Oldfied EH:  Induction of glioblastoma multiforme in nonhuman primates after therapeutic doses of fractionated whole brain radiation therapy.  J Neurosurg 97(6): 1378-1389, 2002.

Zabramski JM, Whiting D, Darouiche RO, Horner TG, Olson J, Robertson C, Hamilton AJ:  Efficacy of antimicrobial-impregnated external ventricular drainage catheters:  A prospective randomized, controlled trial.  J Neurosurg.  98(4):725-730, 2003.

Bowers G, He J, Schultz K, Olavarria G, Maneval D, Olson JJ:  Efficacy of adenoviral p53 delivery with SCH58500 in the intracranial 9L and RG2 models.  Frontiers in Bioscience.  8:a54-61, May 1, 2003.

Olivi A, Grossman SA, Tatter S, Barker F, Judy K, Olson J, Bruce J, Hilt D, Fisher J, Piantadosi S:  Dose escalation of Carmustine in surgical implanted polymers in patients with recurrent malignant glioma:  A New Approaches to Brain Tumor Therapy CNS Consortium Trial.  J Clinical Oncology 21(9): 1845-1849, 2003.

McConathy J, Martarello L, Malveaux EJ, Camp VM, Simpson NE, Simpson CP, Bowers GD, Zhang Z, Olson JJ, Goodman MM: Synthesis and evaluation of 2-amino-4-[(18)F]fluoro-2-methylbutanoic acid (FAMB): relationship of amino acid transport to tumor imaging properties of branched fluorinated amino acids.  Nucl Med Biol 30(5): 477-490, 2003.

Hunter SB, Brat DJ, Olson JJ, von Deimling A, Zhou W, Ven Meir EG:  Alterations in molecular pathways in diffusely infiltrating glial neoplasms: application to tumor classification and anti-tumor therapies.  Int J Oncol.  23(4):857-869, 2003.

Tatter SB, Shaw EG, Rosenblum ML, Karvelis KC, Kleinberg L, Weingart J, Olson JJ, Crocker IR, Brem S, Pearlman JL, Fisher JD, Carson KA, Grossman SA:  An inflatable balloon catheter and liquid 125I radiation source (Gliasite Radiation Therapy System) for treatment of recurrent glioma: multicenter and feasibility study.  J Neurosurg 99:297-303, 2003. 

Narayan P, Crocker I, Elder E, Olson JJ:  Safety and efficacy of concurrent interstitial radiation and hyperthermia in the treatment of progressive malignant brain tumors.  Oncology Reports. 11: 97-103, 2004.

Schinazi RF, Hurwitz SJ, Liberman I, Glazkova Y, Mourier NS, Olson J, Keane T:  Tissue disposition of 5-o-carboranyluracil – A novel agent for boron neutron capture therapy of prostate cancer.  Nucleosides, Nucleotides, and Nucleic Acids 23:  291-306, 2004. 

Junge CE, Lee CJ, Hubbard KB, Zhang Z, Olson JJ, Hepler JR, Brat DJ, Traynelis ST:  Protease-activated receptor-1 (PAR1) in human brain:  localization and functional expression in astrocytes.  Experimental Neurology 188: 94-103, 2004.

Olson JJ, James D, Lawson D, Hunter S, Tang G, Billingsley J:  Correlation of the response of recurrent malignant gliomas treated with interferon with tumor interferon a gene content.  Int J Oncol 25: 419-427, 2004.

Phuphanich S, Brat DJ, Olson JJ: Delivery systems and molecular targets of mechanism-based therapies for GBM.  Review.  Expert Rev Neurother 4(4):649-663, 2004.    

Chiocca EA, Abbed KM, Tatter S, Louis DN, Hochberg FH, Barker F, Kracher J, Grossman SA, Fisher JD, Carson K, Rosenblum M, Mikkelsen T, Olson J, Markert J, Rosenfeld S, Nabors LB, Brem S, Phuphanich S, Freeman S, Kaplan R, Zwiebel J. Related Articles, Links  A Phase I Open-Label, Dose-Escalation, Multi-Institutional Trial of Injection with an E1B-Attenuated Adenovirus, ONYX-015, into the Peritumoral Region of Recurrent Malignant Gliomas, in the Adjuvant Setting. Mol Ther 10(5):958-66, 2004.

Post DE, Devi NS, Li Z, Brat DJ, Kaur B, Nicholson A, Olson JJ, Zhang Z and Van Meir EG Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors. Clin Cancer Res 10(24): 8603-8612, 2004.

Phuphanich S, Brat DJ, Olson JJ:  Delivery systems and molecular targets of mechanism-based therapies for GBM.  Expert Review of Neurotherapeutics.  4(4):649-63, 2004. 

Tan C, de Noronha RG, Roecker AJ, Pyrzynska B, Khwaja F, Zhang Z, Zhang H, Teng Q, Nicholson AC, Giannakakou P, Zhou W, Olson JJ, Pereira MM, Nicolaou KC, and Van Meir EG:  Identification of a novel small molecule inhibitor of the hypoxia-inducible factor-1 (HIF-1) pathway. Cancer Res 65(2): 605-612, 2005.

Hunter SB, Varma V, Shehata B, Nolen JDL, Cohen C, Olson JJ, Ou CY:  Apolipoprotein D expression in primary brain tumors: Analysis by quantitative RT-PCR in formalin-fixed, paraffin-embedded tissue.  J Histochem Cytochem 53:963-969, 2005.

Macdonald DR, Kiebert G, Prados M, Yung A, Olson J: Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life. Cancer Investigation. 23(2):138-44, 2005.

Khwaja FW, Nolen JD, Mendrinos SE, Lewis MM, Olson JJ, Pohl J, Van Meir EG, Ritchie JC, Brat DJ:  Proteomic analysis of cerebrospinal fluid discriminates malignant and nonmalignant disease of the central nervous system and identifies specific protein markers.  Proteomics 6:6277-87, 2006.

Kang SH, Cho HT, Devi S, Zhang Z, Escuin D, Liang Z, Mao H, Brat DJ, Olson JJ, Simons JW, LaVallee TM, Giannakakou P, Van Meir EG, Shim H.  Antitumor Effect of 2-Methoxyestradiol in a Rat Orthotopic Brain Tumor Model.  Cancer Res 66: 11991-1997, 2006.

Chhabra VS, Zhang J, Olson JJ: Association between an arachnoid cyst and intracranial aneurysms misdiagnosed as a cystic tumor with a mural nodule. Neursurgical Focus 22: E3, 2007

Khwaja FW, Reed MS, Olson JJ, Schmotzer BJ, Gillespie GY, Guha A, Groves MD, Kesari S, Pohl J and Van Meir EG: Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients. J Proteome Res 6, 559-570, 2007.

Tehrani M, Friedman T, Olson JJ, Brat DJ. Intravascular thromombosis in central nervous system malignancies: potential role in astrocytoma progression to glioblastoma. Brain Pathol 18: 164-171, 2008.

Olson JJ, Zhang Z, Dillehay D, Stubbs J: Assessment of a balloon-tipped catheter modified for intracerebral convection-enhanced delivery. J Neuro-oncology 89 : 159 - 168, 2008

Yu W, Williams L, Malveaux E, Camp VM, Olson JJ. Goodman MM: Synthesis and evaluation of [123I] labeled iodovinyl amino acids syn-, anti-1-amino-3-[2-iodoethenyl]-cyclobutane-1-carboxylic acid, and 1-amino-3-iodomethylene-cyclobutane-1-carboxylic acid as potential SPECT brain tumor imaging agents. Bioorganic & Medicinal Chemistry Letters. 18(4):1264-8, 2008.

Grossman SA, Olson J, Batchelor T, Peereboom D, Lesser G, Desideri S, Ye X, Hammour T, Supko JG. New Approaches to Brain Tumor Therapy CNS Consortium. Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma. Neuro-Oncology. 10(2):190-8, 2008.

Phuphanich S, Carson KA, Grossman SA, Lesser G, Olson J, Mikkelsen T, Desideri S, and Fisher JD: Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma. Neuro-oncology 10: 617-23, 2008.

Olson JJ, Ryken TC: Guidelines for the Treatment of Newly Diagnosed Glioblastoma: Introduction. Journal of Neuro-oncology 89: 255-258, 2008.

Mukundan S, Holder CA, Olson JJ: Neuroradiological Assessment of Newly Diagnosed Glioblastoma. Journal of Neuro-oncology 89: 259-269, 2008.

Ryken TC, Frankel B, Julien T, Olson JJ: Surgical Management of Newly Diagnosed Glioblastoma in Adults: Role of Cytoreductive Surgery. Journal of Neuro-oncology 89: 271-286, 2008.

Brat, DJ, Prayson RA, Ryken TC, Olson JJ: Diagnosis of Malignant Glioma: Role of Neuropathology. Journal of Neuro-oncology 89: 287-311, 2008.

Buatti J, Ryken, R, Smith MC, Sneed P, Suh J, Mehta M, Olson JJ: Radiation Therapy of Pathologically Confirmed Newly Diagnosed Glioblastoma in Adults. J Neuro-oncology 89: 313-337, 2008.

Fadul CE, Wen PY, Kim L, Olson JJ: Cytotoxic Chemotherapeutic Management of Newly Diagnosed Glioblastoma Multiforme. J Neuro-oncology 89: 339-357, 2008.

Olson JJ, McKenzie E, Skurski-Martin M, Zhang Z, Brat D, Phuphanich S. Phase I analysis of BCNU-impregnated biodegradable polymer wafers followed by systemic interferon alfa-2b in adults with recurrent glioblastoma multiforme. J Neurooncol. 2008 Dec;90(3):293-9. Epub 2008 Aug 5. PubMed PMID: 18679580.

Kaur B, Sandberg E, Devi N, Zhang Z, Klenotic P, Febbraio M, Shim H, Mao H, Cork S, Silverstein R, Brat D, Olson J, Van Meir E:  Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism.  Cancer Research 69:1212–20, 2009. 

Rong Y, Chen G, Tucker-Burden C, Durden D, Van Meir E, Olson JJ; Mackman N, Brat D:  EGFR and PTEN Modulate Tissue factor Expression in Glioblastoma Through JunD/AP-1 Transcriptional Activity. Cancer Res 69:  2540-2549, 2009.

Olson JJ, Fadul CE, Brat DJ, Mukundan S, Timothy C. Ryken TC:  Management of Newly Diagnosed Glioblastoma:  Guidelines Development, Value and Applications.  J Neuro-oncol 93:  1-23, 2009.. 

Bellail AC, Tse MCL, Song JH, Phuphanich S, Olson JJ, Sun SY, Hao C:  DR5-mediated DISC controls caspase-8 cleavage and initiation of apoptosis in human glioblastomas.  J. Cell. Mol. Med (EPub ahead of print) May, 2009

Yu W, McConathy J, Williams L, Vernon M. Camp VM, Malveaux EJ, Zhang Z, Olson JJ, Goodman MM:  Synthesis, Radiolabeling, and Biological Evaluation of (R)- and (S)-2-Amino-3-[18F]Fluoro-2-Methylpropanoic Acid (FAMP) and (R)- and (S)-3-[18F]Fluoro-2-Methyl-2-N-(Methylamino)propanoic Acid (NMeFAMP) as Potential PET Radioligands for Imaging Brain Tumors.  J Med Chem 53:  876–886, 2010. 

Gaspar LE, Mehta MP, Patchell RA, Burri SH, Robinson PD, Morris RE, Ammirati M, Andrews DW, Asher AL, Cobbs CS, Kondziolka D, Linskey ME, Loeffler JS, McDermott M, Mikkelsen T, Olson JJ, Paleologos NA, Ryken TC, Kalkanis SN:  The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: A systematic review and evidence-based clinical practice guideline.  J Neuro-oncology 96: 17-32, 2010. 

Kalkanis SN, Kondziolka D, Gaspar LE, Burri SH, Asher AL, Cobbs CS, Ammirati M, Robinson PD, Andrews DW, Loeffler JS, McDermott M, Mehta MP, Mikkelsen T, Olson JJ, Paleologos NA, Patchell RA, Timothy C. Ryken TC, Linskey ME:  The role of surgical resection in the management of newly diagnosed brain metastases: A systematic review and evidence-based clinical practice guideline.  J Neuro-oncology 96: 33-43, 2010. 

Linskey ME, Andrews DW, Asher AL, Burri SH, Douglas Kondziolka D, Robinson PD, Ammirati M, Cobbs CS, Gaspar LE, Loeffler JS, McDermott M, Mehta MP, Mikkelsen T, Olson JJ, Paleologos NA, Patchell RA, Ryken TC, Steven N. Kalkanis SN:  The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: A systematic review and evidence-based clinical practice guideline.  J Neuro-oncology 96: 45-68, 2010. 

Mehta MP, Paleologos NA, Mikkelson T, Robinson PD, Ammirati M, Andrews DM, Asher AL, Burri SH, Cobbs CS, Gaspar LE, Kondziolka D, Linskey ME, Loeffler JS, McDermott M, Olson JJ, Patchell RA, Ryken TC, Kalkanis SN:  The role of chemotherapy in the management of newly diagnosed brain metastases: A systematic review and evidence-based clinical practice guideline.  J Neuro-oncology 96: 71-83, 2010. 

Ammirati M, Cobbs CS, Linskey ME, Paleologos NA, Ryken TC, Burri SH, Asher AL, Loeffler JS, Robinson PD, Andrews DW, Gaspar LE, Kondziolka D, McDermott M, Mehta MP, Mikkelsen T, Olson JJ, Patchell RA, Kalkanis SN:  The role of retreatment in the management of recurrent / progressive brain metastases: A systematic review and evidence-based clinical practice guideline.  J Neuro-oncology 96: 85-96, 2010. 

Mikkelsen T, Paleologos NA, Robinson PD, Ammirati M, Andrews DM, Asher AL, Burri SH, Cobbs CS, Gaspar LE, Kondziolka D, Linskey ME, Loeffler JS, McDermott M, Mehta MP, Olson JJ, Patchell RA, Ryken TC, Kalkanis SN:  The role of prophylactic anticonvulsants in the management of brain metastases: A systematic review and evidence-based clinical practice guideline.  J Neuro-oncology 96: 97-102, 2010. 

Ryken TR, McDermott M, Robinson PD, Ammirati M, Andrews DW, Asher AL, Burri SH, Cobbs CS, Gaspar LE, Kondziolka D, Linskey ME, Loeffler JS, Mehta MP, Mikkelsen T, Olson JJ, Paleologos NA, Patchell RA, Kalkanis SN:  The role of steroids in the management of brain metastases: A systematic review and evidence-based clinical practice guideline.  J Neuro-oncology 96: 103-114, 2010. 

Olson JJ, Paleologos NA, Gaspar LE, Robinson PD, Morris RE, Ammirati M, Andrews DW, Asher AL, Burri SH, Cobbs CS, Kondziolka D, Linskey ME, Loeffler JS, McDermott M, Mehta MP, Mikkelsen T, Patchell RA, Ryken TC, Kalkanis SN:  The role of emerging and investigational therapies for metastatic brain tumors: A systematic review and evidence-based clinical practice guideline of selected topics.  J Neuro-oncology 96: 115-142, 2010. 

Phuphanich S, Supko JG, Carson KA, Grossman SA, Nabors LB, Mikkelsen T, Lesser G, Rosenfeld R, Desideri S, Olson JJ:  Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma.  J Neurooncol, 100: 95-103, 2010. 

Schuette AJ, Taub JS, Hadjipanayis CG, Olson JJ:  The Role of Biopsy in Patients with Acute Progressive Neurological Decline and Absence of Mass Lesion. Neurology 75:  419-24, 2010.

Roberts CC, Daffner RH, Weissman BN, Bancroft L, Bennett DL, Blebea JS, Bruno MA, Fries IB, Germano IM, Holly L, Jacobson JA, Luchs JS, Morrison WB, Olson JJ, Payne WK, Resnik CS, Schweitzer ME, Seeger LL, Taljanovic M, Wise JN, Lutz ST:  ACR Appropriateness Criteria® on Metastatic Bone Disease.  J Am Coll Radiol 7:400-409, 2010. 

Yan D., Ng WL., Zhang X, Wang P, Zhang Z, Mo YY, Mao H, Hao C, Olson JJ, Curran WJ, Wang Y:  Targeting DNA-PKcs and ATM with miR-101 Sensitizes Tumors to Radiation.  PLoS ONE 5 (e11397):  1-8, 2010 .

Raore B, Schniederjan M, Prabhu R, Brat DJ, Shu HK, Olson JJ:  Metastasis Infiltration: An investigation of the post operative brain-tumor interface.  International Journal of Radiation Oncology, Biology and Physics, e-Pub ahead of print [http://www.ncbi.nlm.nih.gov/pubmed/20971574], Oct 22, 2010. 

Egan KM, Thompson RC, Nabors LB, Olson JJ, Brat DJ, Larocca RV, Brem S, Moots PL, Madden MH, Browning JE, Ann Chen Y. Cancer susceptibility variants and the risk of adult glioma in a US case-control study. J Neurooncol. 2011 Jan 4. [Epub ahead of print] PubMed PMID: 21203894.]

Return to top


Review Articles:

Olson JJ: Recurrent gliomas. Neurosurgical Consultations Vol. 3(18), 1992.

James CD, Olson JJ: Molecular genetics and molecular biology advances in brain tumors. Current Opinion in Oncology 8: 188-195, 1996.

Suh DY, Olson JJ: Management of recurrent malignant primary brain tumors. Part I: Etiology, clinical diagnosis, and treatment options. Contemporary Neurosurgery 20 (11), June, 1998.

Suh DY, Olson JJ: Management of recurrent malignant primary brain tumors. Part II: Chemotherapy, radiation and radiosurgery, brachytherapy, and decision making. Contemporary Neurosurgery 20 (12), June, 1998.

Olson JJ: Neurosurgical Advances in the Treatment of Brain Tumors. Current Oncology Reports 2: 434-437, 2000.

Narayan P, Olson JJ: Management of Anaplastic Astrocytomas. Contemporary Neurosurgery 23 (24), 2001.

Return to top


Texts:

Skull Base Surgery: Basic Techniques. Moore CE, Olson JJ (eds.), Plural Publishing, San Diego, CA, 2010.

Return to top


Book Chapters:

Morgan JS, Olson JJ: Steroid hormones and meningiomas. Meningiomas and Their Surgical Management, H.H. Schmidek (ed.), W.B. Saunders, Philadelphia, pp. 48-55. 1991.

Olson JJ, Reisner A: Craniotomy for Brain Tumor in M.F. Lubin, K. Walker, R.B. Smith, III (eds), Medical Management of the Surgical Patient, 3rd Ed. J.B. Lippincott, Philadelphia, 1994.

Olson JJ, Rossi J: Radiobiology of the Central Nervous System. Tindall GT, Cooper P, Barrow D (eds) Practice of Neurosurgery, Williams and Wilkins, Baltimore, 1996. pp. 575-600.

Bingaman K, Olson JJ: Cranial Bone Flap Infections and Osteomyelitis of the Skull, in Osenback RK, and Zeidman SM (eds): Infections of the Central Nervous System: Diagnosis and Management. Lippincott-Raven, Philadelphia, 1999. pp. 65-84.

Olson, JJ, Barrow D, Gilbert M, Oyesiku N: Intracranial Tumors in Morris PJ, Wood WC (eds) Oxford Textbook of Surgery. Oxford University Press, New York, 2000. pp. 2801-2828.

Shinazi RF, Hurwitz S, Liberman I, Juodawlkis A, Shi J, Liotta DC, Coderre J, Olson J: Preclinicl Development of b-D-5-o carboranyl-2’-deoxyuridine (D-CDU) for the Treatment of Malignant Brain Tumors in Hawthorne F, et al (eds): Frontiers in Neutron Capture Therapy. Kluver Academic/Plenum Publishers, New York, 2001. pp. 1121-1124.

Olson JJ, Bowers G, Zhang Z: Proteasome inhibitors in a brain tumor model, in Adams J (ed) Cancer Drug Discovery and Development: Proteasome Inhibitors in Cancer Therapy. Humana Press, Inc., Totowa, NJ, 2004. Pp. 161-70.

Return to top